Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in ...

D models of uveal melanoma are transforming cancer research, enabling personalized treatments and better drug testing for ...

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in ...

The summer of 2023 saw the approval of a new treatment option for certain patients with uveal melanoma, a form of cancer that begins in the eye and remains a challenge to treat. Richard Staines ...

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in adults. Their goal is to use these models to better understand how this ...

After a Stage 4 cancer diagnosis and a prognosis of 16 months to live, Katie Doble didn’t know whether she should plan her ...

ROCHESTER, Minnesota — Mayo Clinic researchers have developed  organoid models  to study  uveal melanoma , one of the most common types of eye cancer ...

Turnstone, which went public via an $80 million IPO in 2023, ended September 2024 with $45.3 million to hand, which the ...

Uveal melanoma is the most common primary malignancy of the eye and frequently leads to metastatic death. Until the mid-20th Century, the only treatment for uveal melanoma was enucleation.

Tebentafusp is recommended, within its marketing authorisation, for treating HLA‑A*02:01-positive unresectable or metastatic uveal melanoma in adults. Tebentafusp is only recommended if the company ...